{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T22:34:37Z","timestamp":1783809277709,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005040","name":"Bontius Stichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To describe the pharmacokinetic properties of the [<jats:sup>18<\/jats:sup>F]fluoro-polyethylene glycol(PEG)-folate radiotracer in PET\/CT imaging of patients with advanced stage epithelial ovarian cancer (EOC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Procedures<\/jats:title>\n                <jats:p>In five patients with advanced EOC (FIGO stage IIIB\/IIIC, F\u00e9d\u00e9ration Internationale de Gyn\u00e9cologie et d\u2019Obst\u00e9trique), a 90-min dynamic PET acquisition of the pelvis was performed directly after i.v. administration of 185\u00a0MBq [<jats:sup>18<\/jats:sup>F]fluoro-PEG<jats:sub>6<\/jats:sub>-folate. Arterial blood samples collected at nineteen timepoints were used to determine the plasma input function. A static volume of interest (VOI) for included tumor lesions was drawn manually on the PET images. Modelling was performed using PMOD software. Three different models (a 1-tissue compartment model (1T2k) and two 2-tissue compartment models, irreversible (2T3k) and reversible (2T4k)) were compared in goodness of fit with the time activity curves by means of the Akaike information criterion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The pharmacokinetic analysis in the pelvic area has proven to be much more challenging than expected. Only four out of 22 tumor lesions in five patients were considered suitable to perform modelling on. The remaining tumor lesions were inapt due to either low tracer uptake, small size, proximity to other [<jats:sup>18<\/jats:sup>F]fluoro-PEG<jats:sub>6<\/jats:sub>-folate -avid structures and\/or displacement by abdominal organ motion in the dynamic scan. Data from the four analyzed tumor lesions suggest that the irreversible 2T3k may best describe the pharmacokinetics. All 22 lesions were immunohistochemically stained positive for the folate receptor alpha (FR\u03b1) after resection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Performing pharmacokinetic analysis in the abdominal pelvic region is very challenging. This brief article describes the challenges and pitfalls in pharmacokinetic analysis of a tracer with high physiological accumulation in the intestines, in case of lesions of limited size in the abdominal pelvic area.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11307-024-01922-0","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:02:07Z","timestamp":1716382927000},"page":"577-584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Challenges in Pharmacokinetic Modelling of [18F]fluoro-PEG-folate PET\/CT Imaging in Epithelial Ovarian Cancer Patients"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9077-0292","authenticated-orcid":false,"given":"Thomas","family":"Ruytenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabeau A.","family":"Ciggaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge T. A.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyanne A.","family":"Noortman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Dibbets-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysanne D. A. N.","family":"de Muynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joeri","family":"Kuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis D.","family":"de Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J. M.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik J. F.","family":"Helmerhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka M.","family":"Pereira Arias-Bouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Vahrmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris H. P.","family":"van Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja N.","family":"Gaarenstroom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lioe-Fee","family":"de Geus-Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"1922_CR1","doi-asserted-by":"publisher","unstructured":"Colombo N, Sessa C, du Bois A et al; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group (2019) ESMO-ESGO Consensus Conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 30(5):672\u2013705. https:\/\/doi.org\/10.1093\/annonc\/mdz062.","DOI":"10.1093\/annonc\/mdz062"},{"issue":"28","key":"1922_CR2","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","volume":"34","author":"AA Wright","year":"2016","unstructured":"Wright AA, Bohlke K, Armstrong DK et al (2016) Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(28):3460\u20133473. https:\/\/doi.org\/10.1200\/JCO.2016.68.6907","journal-title":"J Clin Oncol"},{"issue":"6","key":"1922_CR3","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A Du Bois","year":"2009","unstructured":"Du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer 115(6):1234\u20131244. https:\/\/doi.org\/10.1002\/cncr.24149","journal-title":"Cancer"},{"issue":"6","key":"1922_CR4","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/cancers12061562","volume":"12","author":"LDAN Muynck","year":"2020","unstructured":"Muynck LDAN, Gaarenstroom KN, Sier CFM et al (2020) Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases. Cancers (Basel) 12(6):1562. https:\/\/doi.org\/10.3390\/cancers12061562","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1922_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2013.03.024","volume":"130","author":"E Despierre","year":"2013","unstructured":"Despierre E, Lambrechts S, Leunen K et al (2013) Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol Oncol 130(1):192\u2013199. https:\/\/doi.org\/10.1016\/j.ygyno.2013.03.024","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1922_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","volume":"338","author":"N Parker","year":"2005","unstructured":"Parker N, Turk MJ, Westrick E et al (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338(2):284\u2013293","journal-title":"Anal Biochem"},{"key":"1922_CR7","doi-asserted-by":"publisher","first-page":"214702","DOI":"10.1016\/j.ccr.2022.214702","volume":"470","author":"L Wagner","year":"2022","unstructured":"Wagner L, Kenzhebayeva B, Dhaini B et al (2022) Folate-based radiotracers for nuclear imaging and radionuclide therapy. Coord Chem Rev 470:214702. https:\/\/doi.org\/10.1016\/j.ccr.2022.214702","journal-title":"Coord Chem Rev"},{"issue":"12","key":"1922_CR8","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1021\/acs.molpharmaceut.7b00415","volume":"14","author":"Q Chen","year":"2017","unstructured":"Chen Q, Meng X, McQuade P et al (2017) Folate-PEG-NOTA-Al18F: A new folate based radiotracer for PET imaging of folate receptor-positive tumors. Mol Pharm 14(12):4353\u20134361. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00415","journal-title":"Mol Pharm"},{"issue":"2","key":"1922_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4191","volume":"15","author":"YY Gent","year":"2013","unstructured":"Gent YY, Weijers K, Molthoff CF et al (2013) Evaluation of the novel folate receptor ligand [18F] fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. Arthritis Res Ther 15(2):1\u20131. https:\/\/doi.org\/10.1186\/ar4191","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1922_CR10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41598-020-57841-x","volume":"10","author":"NJ Verweij","year":"2020","unstructured":"Verweij NJ, Yaqub M, Bruijnen ST et al (2020) First in man study of [18F] fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis. Sci Rep 10(1):1047. https:\/\/doi.org\/10.1038\/s41598-020-57841-x","journal-title":"Sci Rep"},{"issue":"1","key":"1922_CR11","doi-asserted-by":"publisher","first-page":"e002108","DOI":"10.1136\/rmdopen-2021-002108","volume":"8","author":"N Verweij","year":"2022","unstructured":"Verweij N, Zwezerijnen G, Ter Wee M et al (2022) Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET. RMD Open 8(1):e002108. https:\/\/doi.org\/10.1136\/rmdopen-2021-002108","journal-title":"RMD Open"},{"issue":"1","key":"1922_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J (2014) FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1\u20135. https:\/\/doi.org\/10.1016\/j.ijgo.2013.10.001","journal-title":"Int J Gynaecol Obstet"},{"issue":"7","key":"1922_CR13","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2967\/jnumed.122.265362","volume":"64","author":"LKS Sundar","year":"2023","unstructured":"Sundar LKS, Lassen ML, Gutschmayer S et al (2023) Fully-automated, fast motion correction of dynamic whole and total-body PET\/CT imaging studies. J Nucl Med 64(7):1145\u20131153. https:\/\/doi.org\/10.2967\/jnumed.122.265362","journal-title":"J Nucl Med"},{"key":"1922_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/oso\/9780195171792.001.0001","volume-title":"Fitting Models to Biological Data using Linear and Nonlinear Regression","author":"H Motulsky","year":"2004","unstructured":"Motulsky H, Christopoulos A (2004) Fitting Models to Biological Data using Linear and Nonlinear Regression. Oxford University Press, New York, p 144"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01922-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-024-01922-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01922-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T09:40:01Z","timestamp":1725270001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-024-01922-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1922"],"URL":"https:\/\/doi.org\/10.1007\/s11307-024-01922-0","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Ethical approval was given by the local medical ethics review board (METC LDD, Leiden, The Netherlands) under application number P20.048. All participants have given written informed consent prior to participation. The trial is registered under EudraCT number: 2020\u2013000112-29, registered on 2021\u201302-27,","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All participants have given written informed consent prior to participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}